Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
50 hedge funds and large institutions have $140M invested in Sierra Oncology, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 10 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
6% more funds holding
Funds holding: 47 → 50 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
41% less capital invested
Capital invested by funds: $240M → $140M (-$99.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$9.66M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$6.4M |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$4.59M |
| 4 |
RIM
RS Investment Management
San Francisco,
California
|
+$2.24M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.93M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.26M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.07M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$806K |
| 5 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$688K |
SRRA Hedge Fund Activity: Q1 2016 in Review
50 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q1 2016, worth a combined $140M — down 41% from $240M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new SRRA positions and 10 closed out — a net gain of 3 holders — while 16 added to existing stakes and 12 trimmed.
The largest buyer was Deerfield Management, adding an estimated $9.66M. The largest seller was OrbiMed, cutting an estimated $2.93M.
- 50 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q1 2016, up from 47 in Q4 2015.
- Funds reported $140M of Sierra Oncology, Inc. Common Stock stock for Q1 2016, down 41% quarter-over-quarter.
- 13 funds opened new Sierra Oncology, Inc. Common Stock positions in Q1 2016 and 10 closed out, a net change of +3 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q1 2016 was Deerfield Management, an estimated $9.66M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q1 2016 was OrbiMed, an estimated $2.93M sold.
Based on aggregated 13F filings for Q1 2016.